The Korean Journal of Medicine

  • 제85권5호
  • /
  • Pages.485-488
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Anti-TNF-${\alpha}$ 치료받은 강직성 척추염에서 체중 및 골밀도 변화

Weight Gain and Improvement of Osteoporosis with Anti-TNF Therapy

  • 김태환 (한양대학교 류마티스병원) ;
  • 윤혜진 (한양대학교 류마티스병원)
  • Kim, Tae-Hwan (Hanyang University Hospital for Rheumatic Diseases, Hanyang University College of Medicine) ;
  • Yun, Hyaejin (Hanyang University Hospital for Rheumatic Diseases, Hanyang University College of Medicine)
  • 발행 : 2013.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

Ankylosing spondylitis (AS) is a chronic inflammatory disorder primarily involving the sacroiliac joints and spine. It usually affects young people, and bone formation and resorption are implicated in the pathogenesis of AS. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line therapy and are very effective in most of patients who have inflammatory back pain. If NSAIDs are not effective, anti-TNF-${\alpha}$ agents are strongly recommended in severe inflammatory back pain. Anti-TNF-${\alpha}$ is very effective in most of AS patients. A study by Lee et al. showed that AS patients who were treated with anti-TNF-${\alpha}$ have weight gain and improvement of osteoporosis. In this editorial, studies on the improvement of weight and osteoporosis with anti-TNF-${\alpha}$ agents are reviewed.

키워드

참고문헌

  1. Longo DL, Fauci FD, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw-Hill, 2012.
  2. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904. https://doi.org/10.1136/ard.2011.151027
  3. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-432. https://doi.org/10.1136/ard.2005.041129
  4. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005;90:3510-3516. https://doi.org/10.1210/jc.2004-1222
  5. Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol 2013; 27:e186-190. https://doi.org/10.1111/j.1468-3083.2012.04571.x
  6. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005; 64:1137-1140. https://doi.org/10.1136/ard.2004.028670
  7. Engvall IL, Tengstrand B, Brismar K, Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 2010;12:R197. https://doi.org/10.1186/ar3169
  8. Alcorn N, Tierney A, Wu O, Gilmour H, Madhok R. Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis 2010;69: 1571. https://doi.org/10.1136/ard.2009.122424
  9. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001;12:605-609. https://doi.org/10.1007/s001980170084
  10. Lee J, Jung M, Kim D, et al. Body weight and bone density changes in patients with ankylosing spondylitis receiving anti-tumor necrosis factor-$\alpha$ treatment. Korean J Med 2013;85:489-494. https://doi.org/10.3904/kjm.2013.85.5.489
  11. Kawai VK, Stein CM, Perrien DS, Griffin MR. Effects of anti-tumor necrosis factor $\alpha$ agents on bone. Curr Opin Rheumatol 2012;24:576-585. https://doi.org/10.1097/BOR.0b013e328356d212
  12. Wendling D. Bone loss in ankylosing spondylitis: can we put the puzzle together? J Rheumatol 2005;32:1184-1185.
  13. Magrey M, Khan MA. Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep 2010;12:332-336. https://doi.org/10.1007/s11926-010-0122-1
  14. Gratacos J, Collado A, Pons F, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 1999;42:2319-2324. https://doi.org/10.1002/1529-0131(199911)42:11<2319::AID-ANR9>3.0.CO;2-G
  15. Klingberg E, Lorentzon M, Mellstrom D, et al. Osteoporosis in ankylosing spondylitis-prevalence, risk factors and methods of assessment. Arthritis Res Ther 2012;14:R108. https://doi.org/10.1186/ar3833
  16. Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:175-182. https://doi.org/10.1136/ard.2007.084426
  17. Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009;68:373-376. https://doi.org/10.1136/ard.2008.091611
  18. Eekman DA, Vis M, Bultink IE, et al. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70: 389-390. https://doi.org/10.1136/ard.2009.127787